Evidence map›Paper›PMID 25999983›Full record

ArticleFrontiers in genetics2015

Exosomal lncRNA-p21 levels may help to distinguish prostate cancer from benign disease.

Mustafa Işın, Ege Uysaler, Emre Özgür, Hikmet Köseoğlu, Öner Şanlı, Ömer B Yücel, Uğur Gezer, Nejat Dalay

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
139citing papers in PubMed, 3 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

139 citing papers in PubMed, 3 syntheses or guidelines pooled it, 205 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

79 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mustafa IşınDepartment of Basic Oncology, Oncology Institute, Istanbul University , Istanbul, Turkey.
Ege UysalerDepartment of Basic Oncology, Oncology Institute, Istanbul University , Istanbul, Turkey.
Emre ÖzgürDepartment of Basic Oncology, Oncology Institute, Istanbul University , Istanbul, Turkey.
Hikmet KöseoğluDepartment of Urology, School of Medicine, Istanbul Hospital, Başkent University , Istanbul, Turkey.
Öner ŞanlıDepartment of Urology, Istanbul Medical Faculty, Istanbul University , Istanbul, Turkey.
Ömer B YücelDepartment of Urology, School of Medicine, Istanbul Hospital, Başkent University , Istanbul, Turkey.
Uğur GezerDepartment of Basic Oncology, Oncology Institute, Istanbul University , Istanbul, Turkey.
Nejat DalayDepartment of Basic Oncology, Oncology Institute, Istanbul University , Istanbul, Turkey.
Istanbul University · TRBaşkent University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exosomes are membranous vesicles containing various biomolecules including lncRNAs which are involved in cellular communication and are secreted from many cells including cancer cells. In our study, investigated the exosomal GAS5 and lincRNA-p21 lncRNA levels in urine samples from 30 patients with prostate cancer (PCa) and 49 patients with benign prostatic hyperplasia. Quantification of lncRNA molecules was performed by real-time PCR. We observed a significant difference in the exosomal lincRNA-p21 levels between PCa and BPH patients whereas the GAS5 levels did not reveal a difference. Our data suggest that the discriminative potential of exosomal lincRNA-p21 levels may help to improve the diagnostic prediction of the malignant state for patients with PCa.

Indexed as

benign prostatic hyperplasiaexosomelncRNAnon-invasive diagnosisprostate cancer

Identifiers

PMID25999983
PMCPMC4422020
OpenAlexW1582095642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.